Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Ausztria1. fázis

First Study Evaluating the Safety and Dosage of YG-01 in Patients With Glioblastoma

A legfontosabb adatok

Ki végzi
YGION Biomedical GmbH
Hol
Vienna (Ausztria)A helyszín megnézése
Azonosító
Állapot
Toborzás még nem indult
Fázis
1. fázis
Résztvevők
15 fő, tervezett
Kezdés
2026. nov.
Várható befejezés
2029. nov.
A vizsgálat típusa
Beavatkozással járó, 2 csoport
A vizsgált kezelések
  • YG-01 Dose Level 1
  • YG-01 Dose Level 2
A regiszteradat frissítve
2026. november 12.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 35 feltétel megnézéseKevesebb

Egyéb feltételek

  • Pre-Production Screening inclusion criteria:
  • Patient provided written informed consent for study participation prior to initiation of any study specific activities/procedures
  • Histologically confirmed glioblastoma, IDH wild type, WHO CNS Grade 4 - classification according to WHO classification of CNS tumors 2021; patients of dose escalation cohorts are required to have undergone extensive tumor resection documented by post-surgical magnetic resonance imaging (MRI) demonstrating either no contrast enhancement or no greater than 1 cm x 1 cm x 1 cm volume of residual enhancing tumor
  • Age ≥18 years
  • ECOG 0-1
  • At least 4 manufacturable neoepitopes identified in a preceding tumor sample analysis study and availability of a manufacturing slot confirmed by the sponsor
  • Stable disease or no measurable disease according to local investigator assessment, following at least two MRI scans taken a minimum of 8 weeks apart, both conducted after the completion of standard 6 weeks radiotherapy with concurrent temozolomide; Pre-Therapy Screening inclusion criteria:
  • Having completed maintenance temozolomide therapy, received at least 4 cycles of temozolomide, and having an interval of at least 4 weeks between the last dose of temozolomide and the first administration of study medication
  • Stable disease or no measurable disease according to local investigator assessment, following an MRI scan taken after the completion of maintenance temozolomide therapy
  • Life expectancy > 3 months at start of study treatment as clinically determined by the investigator
  • ECOG 0-1
  • Availability of study medication confirmed by the sponsor
  • Absolute lymphocyte count (ALC) >0.75 x10\^9/L
  • No need for dexamethasone or any other steroid treatment within 1 week prior to baseline
  • No need for bevacizumab treatment within 1 week prior to baseline; Pre-Production Screening exclusion criteria:
  • Known HIV or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Immunosuppression, not related to treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding; Pre-Therapy Screening exclusion criteria:
  • Abnormal (≥ grade 2 CTCAE v6.0) laboratory values for hematology, liver and renal function (serum creatinine)
  • HIV infection or active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or known infections that can cause a severe disease and pose a severe danger to lab personnel working on patient's blood or tissue
  • Concurrent participation in another interventional clinical trial studying a drug or treatment regimen
  • Clinically relevant autoimmune diseases (with the exception of autoimmune thyroid disease) that, in the investigator's judgement, may interfere with study participation
  • Any vaccination within 2 weeks prior to baseline
  • Immunosuppression, not related to prior treatment for glioblastoma
  • History of severe hypersensitivity reactions
  • Any condition that in the judgment of the investigator interferes with the probability that an individual patient may receive and benefit from YG-01 treatment (e.g., high risk of early disease progression / recurrence; immunocompromised status; anticipated compliance issues)
  • Clinically relevant illness or condition which may affect the patient's safety during the study or impede the patient's ability to complete the study, as assessed by the investigator
  • History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) unless the patient has been disease-free for the last 5 years
  • Pregnancy or breastfeeding

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

A feltételkérdéseket egy MI-rendszer írta a(z) NCT07930338 vizsgálathoz közzétett feltételekből. Szoftver ellenőrizte, nem orvos.

  • How old are you?

Ez a vizsgálat jelenleg itt érhető el: Ausztria.

  • Medical University of ViennaVienna, AusztriaRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is a first-in-human, open-label, single-arm, dose-escalation Phase 1 clinical study evaluating the safety, tolerability, feasibility, and immunogenicity of the YG-01, a personalized neoantigen peptide-based cancer immunotherapy, in patients with diagnosed glioblastoma following standard-of-care therapy. The study will assess the safety and tolerability of repeated administrations of YG-01 and explore immune responses and clinical outcomes following treatment. The study includes sequential dose-escalation cohorts to evaluate the safety and tolerability of increasing dose levels of YG-01 and to identify a recommended dose for further clinical development.

A vizsgálat 2 csoportja

  • Dose Level 1A vizsgált kezelés

    Patients receive YG-01, a personalized neoantigen immunotherapy comprising patient-specific neoepitope peptides administered subcutaneously at Dose Level 1.

    Kezelés: YG-01 Dose Level 1

  • Dose Level 2A vizsgált kezelés

    Patients receive YG-01 at Dose Level 2 subcutaneously on the same schedule as Dose Level 1, started after Safety Committee review of Dose Level 1.

    Kezelés: YG-01 Dose Level 2

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on és az EU hivatalos vizsgálati nyilvántartásában (CTIS).
Hivatalos cím
Phase 1 Dose-escalation Study of YG-01 in Patients With Glioblastoma
Kérdések a feltételekről
Forrás: NCT07930338: ki vehet részt
A regiszteradat frissítve
2026. november 12.